BAT's 2023 Financial Report: New Categories Drive Revenue Growth

BAT by 2FIRSTS.ai
Feb.09.2024
BAT's 2023 Financial Report: New Categories Drive Revenue Growth
BAT Releases 2023 Financial Report: Non-combustible category revenue now accounts for 16.5% of group revenue, increasing 170 basis points from 2022.

British American Tobacco (BAT) released its financial report for the year 2023 on February 8. The report highlights the robust sales of Vuse and Velo, which have driven the revenue growth in new categories including vaporization, heat-not-burn (HNB), and oral products. The income from non-combustible categories now accounts for 16.5% of the group's total revenue, representing an increase of 170 basis points compared to the fiscal year 2022.

 

Other key points are as follows:

 

The conglomerate's revenue has decreased by 1.3%, with an organic growth of 3.1% (measured at constant exchange rates), driven by a significant increase of 21.0% in organic revenue from new categories.

 

A new category, including atomized, HNB, and oral products, achieved profitability in 2023, surpassing the original goal by two years. This led to an increase in the group's profits by £398 million.

 

The conglomerate has reached a global settlement with Philip Morris International (PMI), resolving all ongoing patent infringement lawsuits between the two parties in relation to heated products (HP) and aerosol products.

 

The overall revenue for combustible products witnessed a marginal increase of 0.6%, while the organic price/composition experienced a positive growth of +6.1%. However, due to the macroeconomic pressures in the United States, there was a decline in total sales, specifically in the high-end market segment, affecting both geographic composition and sales volume.

 

AME (America and Europe Market) and APMEA (Asia Pacific Middle East Market) have demonstrated strong performance. The report shows that the new categories, including aerosol, heat-not-burn, and oral products, have achieved profits of 1.67 billion pounds and 610 million pounds respectively in these two markets.

 

The reported operating loss amounted to £15.751 billion (with a decline of 95.8 percentage points in the reported operating profit margin, reaching -57.7%), primarily influenced by a non-cash impairment charge of £27.6 billion associated with the US operations (£273 billion).

 

Adjusted organic operating profit increased by 3.9% at constant exchange rates, while the adjusted organic operating profit margin rose by 40 basis points to reach 45.6%.

 

According to the report, the diluted earnings per share amounted to -646.6 pence. However, after adjusting for organic factors, the diluted earnings per share saw a growth of 5.2% at a constant exchange rate.

 

The operating cash flow conversion rate has reached 100%, indicating that the company efficiently converts its operating cash flow into positive cash flow. However, the adjusted net debt-to-EBITDA ratio has declined to 2.6 times, reflecting a decrease in the company's financial leverage after adjusting for organic factors.

 

The dividend has grown by 2.0% to 235.52 pence, in line with the gradual increase in dividends.

 

Sustained ESG Progress - MSCI Rating Upgraded to A Grade in 2023 (2022: BBB) Two Years Ahead of Schedule, Exceeding Water Consumption and Waste Generation Targets.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | JT Refreshes Ploom CUBE Design and Expands Japan Retail Distribution, Targeting Younger Men and Female Users
Product | JT Refreshes Ploom CUBE Design and Expands Japan Retail Distribution, Targeting Younger Men and Female Users
Japan Tobacco (JT) launched a refreshed Ploom CUBE design in Japan on September 8, 2026, with broader convenience-store and tobacco-retail distribution planned from October 13. The updated device retains the existing Rounded Cube form and heating platform while replacing four previous body colors with Pebble White and Cobalt Black. JT is also introducing new Front Panels and Fabric Back Covers, although the new accessories are not compatible with the previous Ploom CUBE design. The company says the update is intended to broaden appeal among younger male and female users.
Sep.09
 PMI Opens Generative AI Center in Portugal to Support Global Operations
PMI Opens Generative AI Center in Portugal to Support Global Operations
According to information released by Portugal’s Trade & Investment Agency (AICEP) in July 2026, Philip Morris International (PMI) has established a global Generative Artificial Intelligence Factory (GenAI Factory) at its Portuguese subsidiary Tabaqueira. The center will support PMI’s global operations by developing and deploying AI solutions focused on industrial process optimization, data analytics, operational automation and AI application development. The initiative strengthens Portugal’s role in PMI’s global technology and innovation network.
Aug.27
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia's new retail tobacco permit system took effect October 1, requiring sellers of vapes, nicotine products and related devices and accessories to obtain a Retail Tobacco Permit for each business location. Virginia ABC said more than 3,000 businesses applied in September alone, creating a processing backlog. Qualifying applicants that filed before October 1 may temporarily operate under a Letter of Authorization. The new store-level permit also sits alongside Virginia's existing vape product directory, where sales of unlisted liquid nicotine or nicotine vapor products can trigger civil penalties starting at $5,000.
Regulations
Oct.03
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.
Sep.14
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14